• FeaSion Maps RNA Polymerase II CTD Phosphorylation

  2026-10-09

  Zhu et al. introduce FeaSion, an integrated strategy that connects RNA polymerase II CTD phosphorylation sites with their interactors, genomic occupancy, regulators, and transcriptional functions. The study expands the known regulatory landscape beyond canonical kinases and phosphatases while showing that individual CTD sites are associated with distinct gene-regulatory and chromatin features.

• Interpreting In Vitro Cancer Drug Responses

  2026-10-09

  Hannah R. Schwartz’s 2022 dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for separating proliferative arrest from cell killing while accounting for differences in response magnitude and timing.

• FeaSion Maps RNA Polymerase II CTD Phosphoregulation

  2026-10-08

  The FeaSion study provides a comparative framework for connecting five RNA polymerase II C-terminal domain phosphorylation sites with interacting proteins, genomic occupancy, regulatory factors, and transcriptional outcomes. Its findings expand the known CTD phosphoregulatory network while showing that site-specific effects are linked to distinct chromatin, gene-class, and developmental programs.

• Sulfo-NHS-LC-Biotin Product Overview

  2026-10-08

  Sulfo-NHS-LC-Biotin (SKU A8003) is described by APExBIO as a water-soluble reagent for covalent biotin labeling of accessible primary amines on proteins, peptides, and cell-surface biomolecules. No matched research paper evidence is available for this overview.

• SAR131675: Reading VEGFR-3 Evidence Across Disease Models

  2026-10-07

  Explore SAR131675 as a VEGFR-3 inhibitor through an evidence-centered analysis of lymphangiogenesis, angiogenesis, tumor biology, and kidney disease research. The article distinguishes reported findings from cross-domain hypotheses and clarifies where the compound’s selectivity is informative—and where it is not.

• Cycloheximide: Research Context and Evidence Limits

  2026-10-07

  Cycloheximide is a translational elongation inhibitor used to examine protein turnover, apoptosis, and translation-dependent cellular responses. This overview separates established research context from supplier-reported applications, evaluates the relevance of a supplied leukemia study, and outlines key limitations affecting interpretation and generalizability.

• IR-1061 for OTN-NIR Deep-Tissue Imaging

  2026-10-06

  IR-1061 is an over-thousand-nanometer near infrared fluorescent dye studied for deep-tissue optical imaging. This overview examines its molecular behavior, polymer-encapsulation context, published findings on PLA stereochemistry, evidence strength, and limits on extending laboratory observations to in vivo or clinical applications.

• Annexin V and the TK1 Resistance Question

  2026-10-06

  A translational perspective on how Annexin V-FITC/7-AAD readouts can connect CDH1–TK1 biology, replication-stress adaptation, and treatment-associated cell death in acute myeloid leukemia without overstating what a dual-fluorescence assay can prove.

• SAR131675: VEGFR-3 Inhibitor Research Context

  2026-10-05

  SAR131675 is best interpreted as a preclinical research tool for studying VEGFR-3 signaling, lymphatic endothelial biology, and tumor-associated vascular remodeling. Evidence supports pathway-focused investigation, but direct relevance to nicotine-associated chronic kidney disease remains unproven.

• RNAPII CTD Phosphorylation: FeaSion Findings

  2026-10-05

  A source-grounded overview of how FeaSion mapped RNA polymerase II CTD phosphorylation, identified candidate regulators, and connected individual phosphorylation sites with transcriptional and chromatin-related functions. The evidence is broad but largely context-dependent, and the supplied study does not establish a role for MTSEA-biotin.

• VEGFC–Macrophage Signaling in NASH Fibrosis

  2026-10-04

  A 2026 Phytomedicine study identifies a hepatocyte-derived VEGFC–VEGFR-3–macrophage axis that contributes to high-fat-diet-associated hepatic fibrosis. By combining pharmacologic inhibition, hepatocyte-specific Vegfc deletion, human datasets, and hepatocyte–macrophage models, the work positions VEGFC as a mechanistic link between metabolic liver injury and inflammatory macrophage behavior.

• MTSEA-biotin for Cysteine-Accessibility Studies

  2026-10-01

  MTSEA-biotin enables selective biotinylation of accessible cysteine residues for biochemical mapping and affinity enrichment. This article explains how to use the reagent as an orthogonal tool when interpreting the RNA polymerase II phosphorylation networks revealed by FeaSion.

• ML365: From TASK1 Mechanism to Translation

  2026-10-01

  A translational framework for using ML365 to connect TASK1 ion-channel pharmacology with neuroinflammation, postoperative cognitive impairment, and rigorous target-validation workflows.

• Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide

  2026-09-30

  Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides Cy3 fluorescence detection for goat-derived IgG in ICC/IF, frozen and paraffin IHC, flow cytometry, and ELISA workflows. It should not be treated as a universal secondary antibody for non-goat primary antibodies, and assay-specific titration and controls are required because no directly matched paper evidence is available here.

• SAR131675: VEGFR-3 Inhibitor Workflow

  2026-09-30

  SAR131675 is a selective ATP-competitive tool for separating VEGFR-3 signaling from broader VEGF-receptor effects in endothelial, tumor, and fibrosis models. This workflow connects biochemical potency with cell-based validation and the VEGFC–macrophage axis highlighted in recent hepatic fibrosis research.

554 records 2/37 page Previous Next 12345 下5页 Last page